Delivery of AIB1 siRNA by Ca 2+ /PEI/heparin composite nanoparticles effectively inhibits the growth of human breast cancer

Here, a novel carrier fabricated by the interaction of negatively charged heparin and positively charged PEI and Ca was investigated to deliver AIB1 siRNA into breast cancer cells both in vitro and in vivo. Ca /PEI/heparin nanoparticles were prepared by simply mixing heparin, PEI and CaCl aqueous so...

Full description

Saved in:
Bibliographic Details
Published in:Journal of materials chemistry. B, Materials for biology and medicine Materials for biology and medicine, 2015-10, Vol.3 (38), p.7623-7630
Main Authors: Cheang, T Y, Xing, Z H, Li, Z L, Zhou, H Y, Wei, J H, Zhou, X, Xu, A W, Lin, Y, Wang, S M
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Here, a novel carrier fabricated by the interaction of negatively charged heparin and positively charged PEI and Ca was investigated to deliver AIB1 siRNA into breast cancer cells both in vitro and in vivo. Ca /PEI/heparin nanoparticles were prepared by simply mixing heparin, PEI and CaCl aqueous solution. Heparin in the Ca /PEI/heparin nanoparticles (40.9% heparin, w/w) decreased the cytotoxicity of PEI. According to the MTT assay, Ca /PEI/heparin NPs are superior to commercial Lipofectamine 2000 considering the safety. The Ca /PEI/heparin NPs are able to deliver siAIB1 into breast cancer cells as effectively as Lipofectamine 2000 both in vitro and in vivo. The in vivo experiment also indicated that the NF-κB/BCL-2 signal pathway might be the downstream signal pathway of AIB1 in regulating breast cancer proliferation and progression.
ISSN:2050-750X
2050-7518
DOI:10.1039/c5tb01490e